AstraZeneca Pharma India has made an announcement regarding the ongoing battle with lung cancer. The pharmaceutical company has been given the go-ahead by the Central Drugs Standard Control Organization (CDSCO), Directorate General of Health Services, Government of India, to import and sell Osimertinib Tablets (TAGRISSO). This marks a new milestone as it provides a new option for treatment of patients suffering from one form of advanced lung cancer.
A New Indication: Enhancing Treatment Options
Osimertinib is now available for use in powerful combination therapy as per the new CDSCO approval. It is now allowed to be used along with pemetrexed and platinum chemotherapy as the initial prescription. This specific prescription is meant for patients with non-small cell lung cancer (NSCLC) who are regionally advanced or have metastasized and possess EGFR exon 19 deletions or exon 21 (L858R) substitution mutations. These mutations are known as driver mutations because they help certain lung cancers grow.
TAGRISSO: Making the Drug Available in India
This is a step forward for AstraZeneca Pharma India in being able to market Osimertinib Tablets in 40 mg and 80 mg dosages (TAGRISSOT) within India, as now these regulatory policies have been met. The company will now take the appropriate measures needed to get the drug into the hands of patients, pending any further legal approvals.
AstraZeneca Pharma India: An Overview on Pharmaceuticals
AstraZeneca Pharma India Limited was one of the most important companies in India’s pharmaceutical industry. The firm is actively engaged in the production, distribution, and marketing of various pharmaceutical goods. Also, it offers services pertaining to clinical trials for an overseas affiliated company, which aids in global pharmaceutical R&D.
Financial Performance: Strong Growth In Q3 FY 25
The TAGRISSO approval has come in the midst of exceptionally strong financial performance from AstraZeneca Pharma India stemming from TAGRISSO approval. The firm reported a remarkable increase in the standalone net profit during the third quarter of fiscal year 2025. Net profit reached a staggering 54.68 crore rupees up from 15.80 crore rupees a year earlier. Operational revenue also recorded tremendous increase, growing by 44% to Rs. 440.29 crores from Rs. 305.79 crores in Q3 FY24.
Market Effect: Widely Traded Stock Price Deviations
AstraZeneca Pharma India’s stock price saw a marginal decline on April 4, 2025, despite the drug Osimeritinib being approved by the Central Drug Standard Control Organization (CDSCO) and the positive financial results of the company. The scrip declined 2.27% and closed at Rs 7,908.50. It demonstrates how much stock prices can change even when the circumstances have improved.
This is the First Treatment Option Available for Adults Suffering from Lung Cancer in India
The approval of TAGRISSO by CDSCO is a landmark step in the oncology arsenal directed at advanced lung cancer treatment in India. It provides further impetus for patients suffering from lung cancer in conjunction with other treatments and showcases the improvements being made to the healthcare ecosystem in India through relentless pharmaceutical advancements.
